Evidence map›Paper›PMID 1309242›Full record

ArticleJournal of virology1992

Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes.

M Rowe, A L Lear, D Croom-Carter, A H Davies, A B Rickinson

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 1992. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 135 papers.

0numbers the graph read from it
0cells of the map it votes in
135citing papers in PubMed
15.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

135 citing papers in PubMed, 357 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Arginine Metabolism SupportsbioRxiv : the preprint server for biology · 2025
    Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Simultaneously Both Expression ofBalkan journal of medical genetics : BJMG · 2021
    Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

75 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

M RoweDepartment of Cancer Studies, University of Birmingham Medical School, United Kingdom.
A L Lear
D Croom-Carter
A H Davies
A B Rickinson
Cancer Research UK Clinical Trials Unit · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

Previous studies on Epstein-Barr virus (EBV)-positive B-cell lines have identified two distinct forms of virus latency. Lymphoblastoid cell lines generated by virus-induced transformation of normal B cells in vitro, express the full spectrum of six EBNAs and three latent membrane proteins (LMP1, LMP2A, and LMP2B); furthermore, these lines often contain a small fraction of cells spontaneously entering the lytic cycle. In contrast, Burkitt's lymphoma-derived cell lines retaining the tumor biopsy cell phenotype express only one of the latent proteins, the nuclear antigen EBNA1; such cells do not enter the lytic cycle spontaneously but may be induced to do so by treatment with such agents as tetradecanoyl phorbol acetate and anti-immunoglobulin. The present study set out to determine whether activation of full virus latent-gene expression was a necessary accompaniment to induction of the lytic cycle in Burkitt's lymphoma lines. Detailed analysis of Burkitt's lymphoma lines responding to anti-immunoglobulin treatment revealed three response pathways of EBV gene activation from EBNA1-positive latency. A first, rapid response pathway involves direct entry of cells into the lytic cycle without broadening of the pattern of latent gene expression; thereafter, the three "latent" LMPs are expressed as early lytic cycle antigens. A second, delayed response pathway in another cell subpopulation involves the activation of full latent gene expression and conversion to a lymphoblastoidlike cell phenotype. A third response pathway in yet another subpopulation involves the selective activation of LMPs, with no induction of the lytic cycle and with EBNA expression still restricted to EBNA1; this type of latent infection in B lymphocytes has hitherto not been described. Interestingly, the EBNA1+ LMP+ cells displayed some but not all of the phenotypic changes normally induced by LMP1 expression in a B-cell environment. These studies highlight the existence of four different types of EBV infection in B cells, including three distinct forms of latency, which we now term latency I, latency II, and latency III.

Indexed as

Gene Expression Regulation, ViralViral Matrix ProteinsAntigens, ViralBase SequenceBlotting, WesternB-LymphocytesDNA, ViralEpstein-Barr Virus Nuclear AntigensFluorescent Antibody TechniqueHerpesvirus 4, HumanMolecular Sequence DataPhenotypeTetradecanoylphorbol AcetateTranscriptional ActivationVirus ActivationAntigens, ViralDNA, ViralEBV-associated membrane antigen, Epstein-Barr virusEpstein-Barr Virus Nuclear AntigensTetradecanoylphorbol AcetateViral Matrix Proteins

Identifiers

PMID1309242
PMCPMC238267
OpenAlexW1754574375

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.